Maraviroc

製品コードS2003 別名:UK-427857

Maraviroc化学構造

分子量(MW):513.67

Maravirocは1種のMIP-1α、MIP-1βとRANTESのケモカイン受容体CCR5阻害剤です。IC50値は3.3 nM、7.2 nM と 5.2 nMそれぞれに分かれます。

サイズ 価格(税別) 在庫  
JPY 16268.00 あり
JPY 11620.00 あり
JPY 44820.00 あり
JPY 127820.00 あり

カスタマーフィードバック(3)

  • CCR5 antagonists block FBS-induced breast cancer cell invasion. 3D reconstruction of FBS-induced invasion into collagen gels by Hs578T (A) or SUM-159 (C) breast cancer cells in presence of CCR5 antagonists (100 nmol/L). The corresponding quantifications (mean ±SEM, n = 3) and analysis (Bonferronit test) are displayed in B and D.

    Cancer Res 2012 72(15), 3839-50. Maraviroc purchased from Selleck.

    (E)CAF-induced migration of Huh7 cells was blocked by antagonists of chemokine receptors. CCR2 antagonist (INCB3284, 100 nM), CCR5 antagonist (Maraviroc, 100 nM) and selective CCR1 and CCR3 antagonists (UCB35625, 100 nM) were added to CAF-CM in the transwell assay.

    Cancer Lett, 2016, 379(1):49-59.. Maraviroc purchased from Selleck.

  • Analysis of receptor mechanisms mediating the induction of MMP-9 expression in THP-1 cells by AFP. Maraviroc, an inhibitor of chemokine receptor CCR5, was added to the cells in the indicated concentrations 1 hour before addition of 50 μg/ml AFP or 150 ng/ml RANTES. After 24 hours of cell stimulation, conditioned media were collected and analyzed for MMP-9 activity by the method of zymography

    2010 Dr. Johanna Weiss of University Hospital Heidelberg. Maraviroc purchased from Selleck.

製品安全説明書

CCR阻害剤の選択性比較

生物活性

製品説明 Maravirocは1種のMIP-1α、MIP-1βとRANTESのケモカイン受容体CCR5阻害剤です。IC50値は3.3 nM、7.2 nM と 5.2 nMそれぞれに分かれます。
ターゲット
CCR5 [3]
(Cell-free assay)
MIP-1α [1]
(Cell-free assay)
RANTES [1]
(Cell-free assay)
MIP-1β [1]
(Cell-free assay)
3.3 nM 5.2 nM 7.2 nM
体外試験

Maraviroc inhibits MIP-1β-stimulated γ-S-GTP binding to HEK-293 cell membranes, indicating its ability to inhibit chemokine-dependent stimulation of GDP-GTP exchange at the CCR5/G protein complex. Maraviroc also inhibits the downstream event of chemokine-induced intracellular calcium redistribution, with IC50s ranging from 7 to 30 nM obtained against MIP-1β, MIP-1α and RANTES. In the same experiments, Maraviroc does not trigger release of intracellular calcium at concentrations up to 10 μM, indicating that it is devoid of CCR5 agonist activity. Consistent with this, Maraviroc fails to induce CCR5 internalization. Maraviroc is active at low nanomolar concentrations against HIV-1 Ba-L. Maraviroc inhibits all 200 pseudotyped viruses with a geometric mean IC90 of 13.7 nM. [1] At concentrations >1000 times the 50% inhibitory concentration, maraviroc did not inhibit other chemokine receptors (CCR1, 2, 3, 4, 7, and 8; CXCR1 and 2) to a clinically relevant degree[3].

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa-P4 cells NYnoTYRiTnWwY4Tpc44h[XO|YYm= NIPCeFkzOCCmYYnz M3;NU2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiQ1PSOUBz\WOncITvdkBmgHC{ZYPz[YQhcW5iSHXMZU1RPCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPEOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIlv\nW|aX;uJJRwKEiLVjDndFEzOCCneIDy[ZN{\WRiaX6gR2hQNXSjdEGwJINmdGy|IHHmeIVzKDJyIHjyd{BjgSClZXzsMYNmdGxiZoXzbY9vKGG|c3H5MEBKSzVyPUCuNkBvVQ>? MWmyNVEzQDZ4Mx?=
rhesus monkey Chem-1 cell Ml;sSpVv[3Srb36gZZN{[Xl? MoXjNVIxKG2rboO= MWHEbZNxdGGlZX3lcpQhd2ZiW{GyOWleNU2LUD2xZYxxcGFiZoLvcUBES1J3IHnuJJJp\XO3czDtc45s\XliQ3jlcU0yKGOnbHygcYVu[nKjbnXzJIFnfGW{IEGyNEBucW6|IHL5JIxqeXWrZDDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKGGwYXz5d4l{NCCNaU2wMlI1KG6P NX7lelFOOjN4OEKzNFg>
human TZM-bl cells MXTGeY5kfGmxbjDhd5NigQ>? MlTyOFghcA>? NGnYZW1CdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QhS0OUNTDy[YNmeHSxcjDpckBpfW2jbjDUXm0u[mxiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJUVZvMTDNS2MzPi2rbnT1Z4VlKGOnbHytZ4VtdCCodYPpc44h[mW2d3XlckB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIHX4dJJme3OrbnegbJVu[W5iSFXLNlk{KGOnbHzzJJRwKFScTT3icEBk\WyuczDh[pRmeiB2ODDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuN|chdk1? MmHxNlQ2PjN5MkO=
CHO cells M3O5bmZ2dmO2aX;uJIF{e2G7 NHXoVWszKGh? MmK1SIl{eGyjY3Xt[Y51KG:oIGuxNlhKZVKDTmTFV{Bnem:vIHj1cYFvKEOFUkWgdoVk\XC2b4KgZ49mgHC{ZYPz[YQhf2m2aDDHZYxxcGGrNjDpckBEUE9iY3XscJMh[W[2ZYKgNkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0yNjRibl2= NITx[3YzODF|N{mzOy=>
HOS cells Mlr5SpVv[3Srb36gZZN{[Xl? MYXBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKEKjLVygbY5n\WO2ZXSgbY4hUE:VIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{YXygbY5n\WO2aX;uMEBKSzVyPUKgcm0> NU\OdHZIOTl4NkS5NlA>
HEK293 cells M171SWZ2dmO2aX;uJIF{e2G7 MkHFTY5pcWKrdHnvckBw\iCqdX3hckBOSVSHMT3t[YRq[XSnZDDBV3AsKHWydHHr[UBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEGuOUBucW6|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2xO{4{KM7ebR?= MXGyN|I1OTB{OR?=
human astrocytes NHLPflZHfW6ldHnvckBie3OjeR?= MlnhNVAxKG6P NIriZXU{OCC2bzC2NEBucW6| MVvCbY5lcW6pIHHm[olvcXS7IITvJGNEWjVxTV;SJIlvKGi3bXHuJIF{fHKxY4n0[ZMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBTPSCKSW[tNUBUTjF4MjDpcoZm[3Srb36gZpkhdWWjc4XybY5oKFSjdDDwdo91\WmwIHX4dJJme3Orb36gZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgN|AhfG9iNkCgcYlveyCob3zsc5dm\CCkeTD2bZJidCCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhOThiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= NICyNo0zOzZ6MkOwPC=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The half-life values of Maraviroc are 0.9 hour in the rat and 2.3 hours in the dog. Following oral administration (2 mg/kg) to the dog, the Cmax (256 ng/ml) occurred 1.5 hours post-dose, and the bioavailability is 40%. For the rat, approximately 30% of the administered dose is absorbed from the intestinal tract. [1] Female RAG-hu mice are challenged vaginally with HIV-1 an hour after intravaginal application of the Maraviroc gel. Maraviroc gel treated mice are fully protected against vaginal HIV-1 challenge in contrast to placebo gel treated mice which all became infected. Vaginal administration of Maraviroc fully protects mice against HIV-1 vaginal challenge. While there is a clear pattern of CD4 T cell decline in placebo-gel treated and viral challenged mice, their levels are stable in mice receiving Maraviroc gel. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Inhibition of chemokine binding to CCR5:

Binding of 125I-labeled MIP-1α, MIP-1β, and RANTES to CCR5 is measured using intact HEK-293 cells stably expressing the receptor or membrane preparations thereof. Briefly, cells are resuspended in binding buffer (50 mM HEPES containing 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin [BSA] and adjusted to pH 7.4) to a density of 2 × 106 cells/ml. For membrane preparations, phosphate-buffered saline (PBS)-washed cells are resuspended in lysis buffer (20 mM HEPES, 1 mM CaCl2, 1 tablet COMPLETE per 50 mL, pH 7.4) prior to homogenization in a Polytron hand-held homogenizer, ultracentrifugation (40,000× g for 30 min), and resuspension in binding buffer to a protein concentration of 0.25 mg/mL (12.5 μg of membrane protein is used in each well of a 96-well plate). 125I-radiolabeled MIP-1α, MIP-1β, and RANTES are prepared and diluted in binding buffer to a final concentration of 400 pM in the assay. Maraviroc dilutions are added to each well to a final volume of 100 μL, the assay plates incubate for 1 hour, and the contents filter through preblocked and washed Unifilter plates which are counted following overnight drying.
細胞試験:

[1]

+ 展開
  • 細胞株: PHA-stimulated PBMC or PM-1 cells
  • 濃度: 0-1 μM
  • 反応時間: 5 days or 7 days
  • 実験の流れ:

    Drug susceptibility assays are performed in 24-well tissue culture plates. Duplicate eight-point dilution series of Maraviroc are prepared in DMSO and medium to yield a final DMSO concentration of 0.1% (vol/vol) in the assay. PHA-stimulated PBMC or PM-1 cells are infected with virus for 1 hour at 37 °C. Cells are subsequently washed once, and 3.6 × 105 PBMC or 2.0 × 105 PM-1 cells are added to each well of assay plates containing diluted Maraviroc. Plates are incubated for 5 days (lab-adapted strains) or 7 days (primary isolates) at 37 °C in a humidified 5% CO2 (vol/vol) atmosphere.


    (参考用のみ)
動物試験:

[2]

+ 展開
  • 動物モデル: Humanized BALB/c-Rag2−/−γc−/− and BALB/c-Rag1−/−γc−/− (RAG-hu) mice
  • 製剤: Dissolved in phosphate-buffered saline, sterile-filtered and adjusted to a final concentration of 4 mg/mL (7.8 mM). A 3.4% gel preparation of hydroxyl-ethyl cellulose (HEC) is added to achieve a final concentration of 5 mM Maraviroc in 2.2% HEC gel.
  • 投薬量: ~64 μg
  • 投与方法: A 25 μL volume of the gel formulation is carefully applied in to the vaginal vault of mice.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (194.67 mM)
Ethanol 100 mg/mL (194.67 mM)
Water Insoluble
体内 順序で溶剤を入れること:
2% DMSO+corn oil
10mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 513.67
化学式

C29H41F2N5O

CAS No. 376348-65-1
保管
別名 UK-427857

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02990312 Not yet recruiting Hiv|Kidney Transplant|HIV Reservoir|CCR5 University of Maryland January 2017 Phase 4
NCT02741323 Recruiting HIV Infections National Institute of Allergy and Infectious Diseases (NIAID) January 2017 Phase 2
NCT02881762 Not yet recruiting Hepatitis C|Human Immunodeficiency Virus University of Maryland|ViiV Healthcare September 2016 Phase 4
NCT02519777 Recruiting HIV Infections National Institute of Allergy and Infectious Diseases (NIAID) March 2016 Phase 4
NCT02625207 Completed Healthy Subjects ViiV Healthcare|Pfizer November 2015 Phase 1
NCT02480894 Completed HIV/AIDS Bristol-Myers Squibb July 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    What’s the vehicle do you recommend to dissolve the compound for in vivo experiments?

  • 回答:

    S2003 Maraviroc can be dissolved in 5% DMSO/castor oil at 62 mg/ml as suspension for oral administration. As to a clear solution for injection, following three vehicles at 10mg/ml will help: 1. 2% DMSO/castor oil; 2. 2%DMSO/sunflower oil; 3. 2%DMSO/30%PEG 300/ddH2O.

CCR信号経路図

相関CCR製品

Tags: Maravirocを買う | Maraviroc ic50 | Maraviroc供給者 | Maravirocを購入する | Maraviroc費用 | Maraviroc生産者 | オーダーMaraviroc | Maraviroc化学構造 | Maraviroc分子量 | Maraviroc代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID